MRPL9

Across TCGA pan-cancer cohorts, MRPL9 RNA differs between tumor and matched normal tissue in 15 of 18 cancer types tested, making tumor–normal expression one of MRPL9’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where MRPL9 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types MRPL9 is over-expressed in tumor, although a few such as KICH show the opposite, repressed pattern.

HNSC, KIRC, and LUAD are the cancer types where MRPL9 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MRPL9 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	IV	+0.915	<.001	12	view →
KIRC	Female	All	+0.403	<.001	12	view →
LUAD	Male	III,IV	+1.078	<.001	11	view →
COAD	Male	IV	+1.040	<.001	11	view →
BLCA	Female	III,IV	+0.797	<.001	10	view →
LIHC	Male	II,III,IV	+1.436	<.001	9	view →
KICH	Female	II,III,IV	−1.492	<.001	8	view →
LUSC	Female	All	+0.962	<.001	8	view →
STAD	Male	II,III,IV	+0.825	<.001	8	view →
BRCA	All	III,IV	+0.613	<.001	6	view →
KIRP	All	II,III,IV	+0.468	.001	6	view →
CHOL	Male	All	+2.710	<.001	5	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 15 lineages.

MRPL9–HNSC

Open the HNSC breakdown →